Trial Profile
A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 22 Nov 2016
Price :
$35
*
At a glance
- Drugs Tecarfarin (Primary) ; Warfarin
- Indications Thrombosis
- Focus Therapeutic Use
- Acronyms EmbraceAC
- Sponsors ARYx Therapeutics
- 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
- 07 Dec 2009 Results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH).
- 08 Jul 2009 Results have been presented in an ARYx Therapeutics media release.